divest

Novartis Divests Ophthalmology Assets to Bausch + Lomb for Up to $2.5 Billion

Novartis has signed an agreement to divest its 'front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company. The transaction is valued at up to $2.5 billion, which marks a strategic move to focus on innovative medicines and growth opportunities.

Clariant Could Divest 25% of Portfolio in Merger

China Greenlights DowDuPont